Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Company Announcement COPENHAGEN, Denmark; June 30, 2022 – Genmab A/S (Nasdaq: GMAB) today announced its…